Palvella Therapeutics (PVLA) Cash from Operations (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Cash from Operations of 10900000.0 for Q1 2026, down 61.05% year-over-year from 27986039.45 in Q1 2025, and down 122.18% quarter-over-quarter from 4906000.0 in Q4 2025.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Cash from Operations (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Cash from Operations for 14 consecutive years, with 10900000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 61.05% year-over-year to 10900000.0; the TTM figure through Mar 2026 stood at 29138000.0 (down 76.53% YoY), while the FY2025 annual figure was 25006000.0, down 130.68% from the prior year.
- Cash from Operations eased to 10900000.0 in Q1 2026 per PVLA's latest filing, from 4906000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 20447000.0 in Q4 2023 and bottomed at 22643000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 7081235.29 across 5 years, with a median of 7900000.0 in 2025.
- Annual changes were most pronounced in 2023 — Cash from Operations soared 258.1% — and 2025, when it sank 514.16%.
- Palvella Therapeutics' Cash from Operations stood at 12933000.0 in 2022, then jumped by 258.1% to 20447000.0 in 2023, then sank by 126.38% to 5393000.0 in 2024, then climbed by 9.03% to 4906000.0 in 2025, then slumped by 122.18% to 10900000.0 in 2026.
- Business Quant data shows PVLA's Cash from Operations at 10900000.0 in Q1 2026, 4906000.0 in Q4 2025, and 7900000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | -12.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.81 Mn |
| Mar 31, 2026 | -10.90 Mn |
| Dec 31, 2025 | -4.91 Mn |
| Sep 30, 2025 | -7.90 Mn |
| Jun 30, 2025 | -5.40 Mn |
| Mar 31, 2025 | -6.80 Mn |
| Dec 31, 2024 | -5.39 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Mar 31, 2024 | -1.10 Mn |
| Dec 31, 2023 | 20.45 Mn |
| Sep 30, 2023 | -9.72 Mn |
| Jun 30, 2023 | -13.43 Mn |
| Mar 31, 2023 | -11.00 Mn |
| Dec 31, 2022 | -12.93 Mn |
| Sep 30, 2022 | -8.78 Mn |
| Jun 30, 2022 | -15.58 Mn |
| Mar 31, 2022 | -22.64 Mn |
| Dec 31, 2021 | -10.94 Mn |
| Sep 30, 2021 | -14.48 Mn |